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SUPPLEMENTARY METHODS 
TCGA data 
Methylation data of 16 cancers types (COAD, STAD, READ, PAAD, THCA, BLCA, BRCA, LGG, PRAD, KIRC, 
KIRP, LUSC, GBM, LUAD, UCEC, LIHC) were downloaded from The Cancer Genome Atlas (TCGA) 
(www.cancergenome.nih.gov). For each tumor type, paired tumors and adjacent normal mucosae 
were analyzed, together with additional unmatched tumors. Sample preparation details can be found 
in the TCGA documentation section. For our analysis, we used the beta-values obtained from the 
level_3 methylation data. Samples were considered hypermethylated when their mean beta-value 
was at least the double of the mean of the controls (considering all probes in the area). 
Cell lines 
Cell lines HCT116, HT-29, DLD-1, SW480, LoVo were obtained from the American Type Culture 
Collection (ATCC) and grown in Dulbecco's Modified Eagle Medium (DMEM)/F12 (1:1) supplemented 
with 100mM Sodium Pyruvate, 200mM L-Glutamine, 10% FBS (Invitrogen), at 37ºC in humidified 95% 
air and 5% CO2. HCT116-DKO cells (HCT116 deficient in both DNA methyltransferases [1]) were 
cultured under the same conditions. 
Methylation data 
Genomic DNA was extracted from peripheral leukocytes by the salting-out procedure (Miller et al, 
1988) QIAmp. The extracted DNA was quantified using a Nano Drop ND 2000c spectrophotometer 
(NanoDrop Thermo scientific, Wilmington, DE) and stored at 4C. 200-600 ng of DNA were treated with 
bisulfite using EZ DNA methylation kit (Zymo Research. Cat. No. D5004) according to manufacturer’s 
recommendations.  The incubation profile was 16 cycles at 95C for 30s, 50C for 60 min and a final 
holding step at 4C [2]. 
DNA methylation profiles were generated using the Illumina Human Methylation 450K BeadChip 
assay (technical details of this array are described elsewhere [3]). This array involves whole genome 
amplification, interrogate the methylation levels of 485,577 CpG sites on bisulfite-treated DNA, 
covering 99% of RefSeq genes and 96% of CpG island regions such as CpG island, island shore and 
shelf, 5’ and 3’ UTRs, and promoter and gene body [3]. The methylation level is represented by the β 
value resulting from the ratio of intensity signal obtained from the methylated allele over the sum of 
methylated and unmethylated allele intensity bead signals. β values may take any value between 0 
(non-methylated) and 1 (completely methylated).  
We used raw *.idat files as a starting point for this pipeline, based on the Bioconductor library 
“minfi”. Here, the outliers were removed by inspecting the overall signal intensity, the distribution of 
M-values and the control probe profile. We also checked on the sex specification obtained from the 
results of the Affymetrix Genome-Wide Human SNP 6.0 array (Affymetrix, Santa Clara, USA), using the 
observed genotypes of SNPs on chromosome X and Y. All individuals who were marked as “male” but 
with significant amount of heterozygous X genotypes (>=1%), or who were marked as “female” but 
with high frequency of homozygous X genotypes (>=80%) or Y genotype readings, were individually 
inspected against original data source.  If no satisfactory correction could be obtained these 
individuals were excluded from further analyses. A clustering between the 19 common SNPs of the 
HumanMethylation450K array and affy 6.0 to check the correct pairing between N-T was performed. 
A total of 17 samples were excluded for these reasons. Thus, a final dataset of 240 arrays was used 
for subsequent analyses.  
Probes with a minfi detection p value > 0.01 exceeding 5% of the samples were annotated as missing, 
we removed probes on chromosomes X and Y and the assays measuring 65 SNPs (from Illumina 
manifest). Afterwards, subset-quantile within array normalization (SWAN) introduced sub-quantile 
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normalization for the methylated and unmethylated channels separately, assuming that the 
distribution of the probes with similar number of CpGs should be similar, irrespective of probe type 
(n=481,019) [4]. Methylation probes with low variability were removed (SD < 0.04). We discarded 
41,082 probes that ambiguously mapped to multiple locations in the human genome with up to two 
mismatches [5].  We excluded a further 11,765 probes that contained SNPs within 10 bp of the CpG 
interrogate (from 1,000 genomes project, CEU population). This resulted in a final set of 430,158 
probes that were used in all further analyses. We mapped the 485,577 Illumina probes to the human 
genome sequence (hg18) using UCSC genome browser having a complete annotation of all genes. 
To set the methylation beta value of each gene promoter we used the median of the beta values of 
probes located at the 5’UTR, and within 1.5 Kb of the TSS according to the UCSC genome browser 
annotation. Probes are listed below:  
 
Gene (HumanMethylation450K array probes) 
PTGES2  (cg01311102 cg13880225 cg14092536 cg22863798 cg14324338 cg10218959 cg138 26862 
cg13833419 cg16020551 cg05930684 cg24730207)  
PTGS2  (cg18335243 cg08482694 cg17419623 cg09461185 cg24887140 cg26564040 cg10180406 
cg25837803 cg23070111 cg25147026 cg16101346)  
PTGES3  (cg04686114 cg12507325 cg03226218 cg16823406 cg08027110 cg20253639 cg07281688 
cg11439834 cg22366350)  
PTGES  (cg04831490 cg17683775 cg14390764)  
TBXA2R  (cg06384607 cg25307468 cg15861540 cg04985611 cg09998229 cg08069088 cg11729169 
cg18738857 cg07481491 cg22 757101 cg19225308 cg01209635 cg23846712 cg05343404)  
PTGER2  (cg21502048 cg16134491 cg26674715 cg06738602 cg20055841 cg08423052 cg23693907)  
AKR1B1 (cg18416881 cg16132520 cg13801416 cg06864853 cg10795359 cg14629509 cg21079345 
cg02215070 cg09957386 cg0816770 6 cg23918923 cg04663564)  
PTGER1  (cg10468702 cg21533997 cg24360651 cg03949996 cg27524460 cg03020379  
PTGIR  cg03311682 cg11822964 cg07844738 cg04706667)  
PTGDR  (cg18369034 cg23022053 cg10837806 cg24089118 cg18242103 cg24989962 cg17929687 
cg02191312 cg05302386 cg09516965)  
PTGER4  (cg06802812 cg08164315 cg06013215 cg03337243 cg17421097 cg02026948 cg04727116 
cg21149775 cg25664622 cg01952088 cg01897756 cg04126707 cg04790357 cg04824304 cg26597539)  
PTGDS  (cg00563932 cg18502630)  
PTGER3  (cg23647191 cg14963735 cg12 739034 cg03726881 cg00915178 cg20785136 cg00781169)  
PTGIS  (cg11746287 cg15543919 cg16537756)  
PTGFR  (cg04410756 cg09685982 cg24022301 cg03949391 cg27046936 cg03495868 cg24924936 
cg00701741 cg02859837 cg19403909)  
PTGS1  (cg13974165 cg00501774 cg10493166 cg14154487 cg12927153 cg13630095)  
HPGD  (cg03772063 cg06366981 cg02822257 cg07372795 cg11073923 cg00906130 cg18164599 
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Table S1. Samples used in this study 
 
Series Tissue Type no of samples Molecular data Data access Reference 






this paper this paper 
Colonomics Healthy mucosa, tumor 






http://www.colonomics.org this paper 




DNA methylation https://tcga-data.nci.nih.gov/tcga/ Weinstein et al 
[6] 
Luo et al. Healthy mucosa, tumor 





DNA methylation GEO: GSE48684 Luo et al [7] 
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Table S2. Nomenclature of the PTGS pathway genes analyzed in this study. 
 
  Gene Protein  Alternative name 
AKR1B1 Aldo-keto reductase family 1, member B1  PGFS (prostaglandin F2alpha synthase)  
HPGD Hydroxyprostaglandin dehydrogenase 15 -(NAD) 
 
PTGDR Prostaglandin D2 receptor  DP 
PTGDS Prostaglandin D2 synthase  
 
PTGER1 Prostaglandin E2 receptor 1  EP1 
PTGER2 Prostaglandin E2 receptor 2  EP2 
PTGER3 Prostaglandin E2 receptor 3  EP3 
PTGER4 Prostaglandin E2 receptor 4  EP4 
PTGES Prostaglandin E2 synthase  
 
PTGES2 Prostaglandin E2 synthase 2  
 
PTGES3 Prostaglandin E2 synthase 3 (cytosolic)  cPGES 
PTGFR Prostaglandin F2alpha receptor  FP 
PTGIR Prostacyclin receptor  IP 
PTGIS Prostacyclin synthase  PGIS 
PTGS1 Prostaglandin-endoperoxide synthase 1  COX-1 (Cyclooxygenase-1) 
PTGS2 Prostaglandin-endoperoxide synthase 2  COX-2 (Cyclooxygenase-1) 
TBXA2R Thromboxane A2 receptor  TP 
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Table S3. Clinicopathological correlates of gene expression in the mucosa of healthy controls (NORMAL) and in CRC patients (ADJACENT MUCOSA and TUMOR)*. 
 
 































































PTGES2 0.4178 0.5689 0.9161 0.8712 0.5026 0.9031 0.9853 0.9289 0.7230 0.3529 0.4890 0.3072 0.8820 0.8061 0.7458 0.7956 0.4485 0.7412 
PTGS2 0.8169 0.7871 0.0660 0.5679 0.3495 0.3174 0.9853 0.9289 0.7985 0.3529 0.4105 0.8277 0.8820 0.8061 0.9810 0.1546 0.9458 0.8752 
PTGES3 0.5617 0.5689 0.3823 0.8712 0.8988 0.1724 0.8277 1.0000 0.7230 0.7501 0.7930 0.7585 0.8820 0.8061 0.9810 0.5410 0.5458 0.8752 
PTGES 0.5617 0.7871 0.3790 0.6451 0.5761 0.2311 0.2800 0.9289 0.7333 0.3529 0.7959 0.9119 0.8820 0.8061 0.9097 0.7956 0.9458 0.8752 
TBXA2R 0.4882 0.7295 0.9385 0.6451 0.5761 0.9031 0.9855 0.9289 0.7230 0.4632 0.4890 0.8277 0.8820 0.8061 0.6911 0.7956 0.9485 0.7412 
PTGER2 0.4178 0.5689 0.0660 0.5679 0.8988 0.3284 0.1304 0.9289 0.8956 0.7808 0.7959 0.0192 0.8820 0.8508 0.9779 0.8311 0.2080 0.8752 
AKR1B1 0.6053 0.5689 0.3990 0.5679 0.8571 0.9031 0.8277 0.9289 0.9431 0.3529 0.7959 0.6058 0.8820 0.8061 0.7458 0.7956 0.9458 0.8752 
PTGER1 0.4882 0.7871 0.2673 0.6793 0.5761 0.9583 0.8277 1.0000 0.8523 0.6061 0.3805 0.9119 0.8820 0.8061 0.6911 0.6756 0.9485 0.8752 
PTGIR 0.7894 0.7871 0.4982 0.8712 0.8653 0.9031 0.4130 0.9289 0.7230 0.3529 0.8753 0.6037 0.8820 0.8061 0.6911 0.8311 0.3156 1.0000 
PTGDR 0.6053 0.5689 0.3790 0.8712 0.3495 0.9031 0.4130 0.6834 0.7230 0.5106 0.0408 0.3072 0.8820 0.8061 0.9810 0.2891 0.2080 0.8752 
PTGER4 0.4882 0.7871 0.4539 0.6238 0.5761 0.9031 0.5524 1.0000 0.9256 0.7808 0.7959 0.6037 0.8820 0.8061 0.9440 0.7956 0.3156 0.8752 
PTGDS 0.4178 0.7295 0.2673 0.6451 0.8988 0.3174 0.0288 1.0000 0.7230 0.5106 0.8753 0.6037 0.8820 0.8061 0.7458 0.7956 0.9458 0.8752 
PTGER3 0.7150 0.7670 0.3790 0.6451 0.8653 0.7221 0.8277 0.9289 0.7985 0.3529 0.7930 0.9855 0.8820 0.8506 0.7458 0.8311 0.9458 0.8752 
PTGIS 0.5617 0.7871 0.3790 0.5679 0.5026 0.9031 0.9663 0.9289 0.7230 0.3529 0.6108 0.8523 0.8820 0.8061 0.9779 0.6756 1.0000 0.8752 
PTGFR 0.4882 0.7871 0.1110 0.6451 0.8988 0.9031 0.5524 0.6834 0.8523 0.3529 0.7673 0.6037 0.8820 0.8061 0.6911 0.7956 0.9458 0.7412 
PTGS1 0.1321 0.7670 0.1268 0.5679 0.3495 0.9031 0.8277 0.9289 0.7230 0.5106 0.0408 0.6037 0.8820 0.8508 0.9779 0.1546 0.9458 0.8752 
HPGD 0.7894 0.5689 0.3790 0.8712 0.8988 0.9031 0.4130 0.8610 0.7985 0.3529 0.7959 0.3011 0.8820 0.8061 0.6911 0.7956 0.2080 0.8752 
* Gene expression was analysed with SurePrint arrays. Data were obtained from the Colonomics project and show Wilcoxon P values adjusted using Benjamin and Hochberg method. 
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Gene expression values in regard to the features that are statistically significant (from Table S3) 
 
NORMAL         
 
TUMOR 
        
             LOCATION 
 




PTGDR     
   
MEAN SD P 
    
MEAN SD P 
site_Left (n=61)     7.4264 0.9349 0.0288 
 
age_<=65 (n=26) 3.3739 1.4867 0.0408 
site_Right (n=39)     8.0669 1.1159   
 
age_>65 (n=74) 2.5285 0.6461   
             
       
AGE 
  
PTGS1     
          
MEAN SD P 
       
age_<=65 (n=26) 4.9576 1.0601 0.0408 
       
age_>65 (n=74) 4.2757 0.9525   
             
       
LOCATION 
 
PTGER2   
          
MEAN SD P 
       
site_Left (n=61) 3.8527 0.8970 0.0192 
       
site_Right (n=39) 4.8345 1.5711   
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Table S4. Clinicopathological correlates of DNA methylation in the mucosa of healthy controls (NORMAL) and in CRC patients (ADJACENT MUCOSA and TUMOR)*. 
 
 




























































PTGES2 0.9670 0.9745 0.5272 0.8843 0.5233 0.7111 1.0000 0.9229 0.6120 0.6366 0.6029 0.9164 0.4045 0.2976 0.9398 0.9712 0.7733 0.6260 
PTGS2 0.7344 0.3879 0.4412 0.7105 0.5233 0.9648 0.0003 0.9229 0.8218 0.9638 0.4661 0.0045 0.9996 0.4973 0.6197 0.8025 0.0776 0.7049 
PTGES3 0.7344 0.9745 0.4412 0.8843 0.8580 0.9648 0.3016 0.9229 0.3513 0.9638 0.1518 0.8415 0.9996 0.9668 0.9398 0.5515 0.6336 0.6993 
PTGES 0.7344 0.9745 0.7467 0.7105 0.3636 0.3876 0.0953 0.9229 0.6120 0.9638 0.2437 0.6323 0.9996 0.9061 0.6239 0.8676 0.7733 0.6993 
TBXA2R 0.7344 0.9745 0.7467 0.9155 0.5233 0.7111 0.0057 0.9996 0.3513 0.9638 0.1518 0.3276 0.4045 0.2812 0.9398 0.0618 0.9840 0.6260 
PTGER2 0.9662 0.8878 0.4412 0.8843 0.4070 0.9648 0.0319 0.9229 0.3513 0.9638 0.1518 0.9164 0.3843 0.2106 0.9398 0.3336 0.7733 0.6993 
AKR1B1 0.6770 0.9745 0.1671 0.9155 0.8369 0.9648 1.0000 0.9996 0.8929 0.2988 0.9795 0.4383 0.9996 0.9162 0.6197 0.9712 0.4973 0.7122 
PTGER1 0.7344 0.9745 0.9477 0.8843 0.5233 0.9648 0.0497 0.9229 0.3513 0.2988 0.9795 0.8415 0.9996 0.2812 0.6197 0.9330 0.4973 0.6993 
PTGIR 0.8839 0.3087 0.1412 0.8843 0.9114 0.9648 0.0120 0.9229 0.9683 0.9638 0.9748 0.6323 0.9996 0.7744 0.9398 0.9350 0.2995 1.0000 
PTGDR 0.3274 0.9917 0.4412 0.8843 0.5839 0.9648 0.0139 0.9229 0.3513 0.9638 0.5581 0.9164 0.4045 0.2812 0.9398 0.8025 0.7733 0.6260 
PTGER4 0.7042 0.9745 0.4412 0.8843 0.5233 0.7111 0.5555 0.9229 0.8218 0.9638 0.9748 0.9549 1.0000 0.2812 0.6239 0.8025 0.7733 0.9950 
PTGDS 0.4550 0.3087 0.3832 0.9155 0.5233 0.9648 0.0003 0.9229 0.9683 0.9638 0.8915 0.9164 0.9996 0.9162 0.9398 0.9712 0.4973 0.9981 
PTGER3 0.7029 0.9745 0.7467 0.8843 0.5233 0.9671 0.0806 1.0000 0.9683 0.9638 0.9748 0.0578 0.9996 0.9668 0.9398 0.9330 0.1363 0.7049 
PTGIS 0.3274 0.3136 0.3832 0.8843 0.5064 0.3792 0.5498 0.9229 0.6120 0.9638 0.2437 0.6323 0.9996 0.4973 0.9398 0.5515 0.7733 0.9950 
PTGFR 0.7042 0.0129 0.0841 0.9155 0.3636 0.0038 0.7648 0.9229 0.6120 0.9638 0.6169 0.9164 0.9996 0.2976 0.6197 0.8025 0.7733 0.6993 
PTGS1 0.7042 0.9745 0.9477 0.8843 0.3636 0.9648 0.0008 0.9229 0.3513 0.9638 0.1745 0.8415 0.5430 0.2812 0.9398 0.3336 0.4973 0.6993 
HPGD 0.7042 0.9745 0.9477 0.8843 0.5233 0.9648 0.1179 0.9229 0.3513 0.9638 0.9748 0.8415 0.9996 0.2106 0.6197 0.9712 0.7733 0.9981 
* Gene expression was analysed with SurePrint arrays. Data were obtained from the Colonomics project and Wilcoxon P values adjusted using Benjamin and Hochberg method..  
Cebola et al, SI 10 







              AGE PTGFR     
 
AGE PTGFR     
 
LOCATION PTGS2     
 
MEAN SD P 
  
MEAN SD P 
  
MEAN SD P 
age_<=65 (n=35) 0.3431 0.0379 0.0129 
 
age_<=65 (n=26) 0.3526 0.0772 0.0038 
 
site_Left (n=61) 0.2091 0.1670 0.0045 
age_>65 (n=26) 0.3940 0.0528   
 
age_>65 (n=74) 0.3830 0.0575   
 
site_Right (n=39) 0.3735 0.2304 NA 
         
     
LOCATION PTGS2     
      
MEAN SD P 
     
site_Left (n=27) 0.1228 0.0791 0.0003 
     
site_Right (n=34) 0.1355 0.0300   
      
TBXA2R     
      
MEAN SD P 
     
site_Left (n=27) 0.2244 0.0396 0.0057 
     
site_Right (n=34) 0.2476 0.0329   
      
PTGER2     
      
MEAN SD P 
     
site_Left (n=27) 0.1770 0.0287 0.0319 
     
site_Right (n=34) 0.1953 0.0306   
      
PTGER1     
      
MEAN SD P 
     
site_Left (n=27) 0.1904 0.0251 0.0497 
     
site_Right (n=34) 0.1969 0.0161   
        
Continued in next page 
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 from Table S4 (continued) 
  
ADJACENT MUCOSA 
      
     
LOCATION PTGIR     
      
MEAN SD P 
     
site_Left (n=27) 0.8312 0.0264 0.0120 
     
site_Right (n=34) 0.8208 0.0169 NA 
      
PTGDR     
      
MEAN SD P 
     
site_Left (n=27) 0.2255 0.0505 0.0139 
     
site_Right (n=34) 0.2432 0.0342   
      
PTGDS 
  
      
MEAN SD P 
     
site_Left (n=27) 0.7668 0.0216 0.0003 
     
site_Right (n=34) 0.7473 0.0214   
      
PTGS1     
      
MEAN SD P 
     
site_Left (n=27) 0.2117 0.0269 0.0008 
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Table S5. Information of CRC patients studied in the expression preliminary analysis and in the DNA methylation dissociation curve analysis. 
 
Id AGE SEX STAGE  Id AGE SEX STAGE 
CR10 49 M I I   ID078 62 M I I  
CR12 65 M I I I   ID102 78 M I I  
CR13 86 F I I I   ID114 76 F I I  
CR15 69 M I I I   ID118 51 F I I I  
CR16 56 F I I I   ID138 80 F I I  
CR17 76 F I I I   ID143 na F I I I  
CR18 75 F I I I   ID145 73 F I I  
CR19 72 F I I I   ID146 65 F I I  
CR20 63 M I I I   ID154 54 M I I I  
BH001 76 M I I I   ID186 56 M I I  
BH002 74 F I I   ID223 75 M I I  
BH003 84 M I I I   ID303 67 F I I  
BH005 71 M I I   ID346 64 M I I  
BH006 59 F I I I   ID369 76 M I I I  
BH007 48 M I I I   ID377 81 M I I I  
BH017 74 F I I   ID385 64 F I I I  
BH021 62 F I I I   ID405 na M na 
BH022 84 F I I I   ID437 59 F I I  
BH026 80 F I I   ID450 56 M I I I  
BH027 64 M I I I   ID495 71 F I I  
BH028 68 M I I I   ID528 63 F I I  
BH038 81 M I I I   ID541 72 M I I  
BH046 67 M I I   ID544 61 F I I I  
BH050 73 M I I   ID549 79 M I I I  
BH051 51 F I I   ID551 58 F I I I  
ID009 67 M I I   ID555 49 F I I I  
ID014 64 F I I   ID557 75 M I I I  
ID016 70 F I I I   ID563 na M na 
ID017 31 F I I I   ID597 na F na 
ID025 67 M I I   ID608 73 F I I I  
ID046 68 M I I   ID628 na F na 
ID063 74 F I I I       
ID072 73 M I I I   
Cebola et al, SI 13 
Table S6. Primers used in this study for the expression analysis of PTGS pathway genes. 
 
Gene Product  position 1  Forward primer  Reverse pr imers  
Product  size  
(bp)  
AKR1B1  chr7:134136426-134143806 CCGTCTCCTGCTCAACAAC TACACATGGGCACAGTCGAT 138 
PTGS1 chr9:125152594-125154599 AAACCCTACACCTCCTTCCA CCCCAATCTCTATCATACTCT 163 
PTGS2 chr1:186643812-186645076 GAATTACCCAGTTTGTTGAATC TTCTACCAGAAGGGCAGGAT  278 
HPGD chr4:175413148-175414389 AATCAATTGAAAAAGAAGAAAA GAAAATGAATTCCCTTAGAA  186 
PTGDR chr14:52735343+52741617  ACCGTGCTCTTCACTATGTG AAATCTTGTGAAAAAATATCCG  205 
PTGDS chr9:139875286+13987611  TAAGTGCATGACGGAACAATA AGGGGCTCGGGGAAGGAA  110 
PTGER1 chr19:14583514-14584209 CTGCTGGAGCCCAATGC TGGCGCAGTAGGATGTAC  144 
PTGER2 chr14:52782009+52794013  GCAGGAGAGGGGAAAGG  AATTGATAAAAACCTAAGAGC  176 
PTGER3 chr1:71478094-71512579 CTTTTCTTCGCCTCTGCCTT TCTTTCTGCTTCTCCGTGTG  290 
PTGER4 chr5:40681909-81373848 ATCTTACTCATTGCCACCT ATTTTTACTGACTTCTCGCT  114 
PTGES chr9:132502095-132515232 CACGCTGCTGGTCATC AGGAAAAGGAAGGGGTAG  218 
PTGES2 chr9:130883406-130884707 GTGGGTGGCTGCTGTGGG  TGCTCTGCGCGGGGACATT  195 
PTGES3 chr12:57058139-57060035 GGTGGTGATGAGGATGT  GGGTTAAAGTAGGCAAATAC 214 
PTGFR chr1:78959186+78963629  CGATAATGTGTGTCTCCTGT CTATGTAAGAAATCACTTTGCT  112 
PTGIR3  chr19:47124350-47124424 GCCGATCAGCTGCTGTTTCT TTTCCTCTGTCCCTCACTCTCTTC 75 
PTGIS 2  chr19:48140729-48156126 CCGTGGCTCCCTGTCAGT GCAGCTTCCACAGGCGAC 72 
TBXA2R chr19:3595775-3599890 TGGGGATCATGGTGGTGG  CGGCGCGGCGGAACAGG  201 
 
1 Genome Browser Version Feb. 2009 (GRCh37/hg19) 
2 from reference [8] (references are listed in page 4) 
3 from reference [9] 
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Table S7. Primers used in this study for dissociation curve analysis and bisulfite sequencing of DNA methylation content. 
 
Gene Outer forward pr imer  Outer reverse primer  Inner forward pr imer  Inner reverse primer  
Product  
size  (bp)  
AKR1B1  GAGTATTTATTTTTTAGGTATT TTTCCCACCAAATACAACA AATTTTAGGATGGGTATTTTG AACTAAAAAACTCCTTTCTAC 325 
HPGD GGGTTTTTTTTTAGTTATTTTT CTATCAACTACCTACCAAT GGAGTGTGTGGGTAGAGAAA  AAACCAAAAACTAAAAAAAAACTT 403 
PTGDR ATTTTAGTAGTTTTTTTTTTGTTT AACACCACCCCAACCCC AAAACCAACAAATTACCCA GAGTTTGTTTTTATTGAGAA 420 
PTGDS TTTTTTGGGAGGAGTGAG  ATTCTATACCCTAACTAAAC  GTTTTATATTTGGGTGTTAG -  304 
PTGER1 AAGAGGTTAGTAAGTAGTGT AAACCTACCACTTCCTAA GAAGAGGTTAGTAAGTAGTG CCTACCACTTCCTAAAC 294 
PTGER2 TAAGTGTTTTTGTATTTTTTTTTA TCCAAAACCCCCTTCCC TTTTTGTATTTTTTTTTAGTTTTTT  ACTTACCCTAAATCTCCC 469 
PTGER3 GAAAAGGTTGTTTTAGTTATG TCACCATACTACTCACTAAT TTGGTGTTGATGAAGTATTA AATCCTTCCTACTATACATC 382 
PTGER4 GGTTAATTTTAGGTAGAATT CCTCTATACAAACTTTTCT GGATAGGAGGTTTAAGAA  TTCTCCTCCTCCAAATT 365 
PTGES GTTTAGTAAGTAGTAGGTG AACTACCATTATCAACTC GTTTAGTAAGTAGTAGGTG AACTACCATTATCAACTCC 395 
PTGES2 TTATAAGTAGGTAGAGG CTAAAAATTCCCTTAAC GTTGATTAGTATTTTTATT CCAAAATCCTAACCCTT 401 
PTGES3 GTttagTaagTagtaggtg  cacaAACTACCATTATCAAC gTaagTagtaggtgTtTaa  AACTACCATTATCAACTCC 383 
PTGFR TAGTATTGTTTTGTGTTTAT TACATTAAAATCAACCTCT GAGAGAAGAGGAAGAGG  AAATAATACCTTATCATCCC 297 
PTGIR GGTAAAGAGGATGAGTATGGA  AATAAATCACCTAAAATCAAAA -  CCAACAAAAACATCTAAATAAAC 427 
PTGIS_A 1  GTTTTTTTTGTTAAGAAGGTGT ATAAATAATTCCAAAACATAATCAAA TTAAGAAGGTGTAAGGTGGG AACACTCCCATCTATATAATAA 316 
PTGIS_B 1  TTTTAAARTGGGTTGGGGTGGG  CCTTCCCACCTTACACCTTCTTA GGAATTTTATTTGGGAGTGGGTT  CACCTTCTTAACAAAAAAAAC 346 
PTGS1 AGATTTAGGTGTATGGTATA TTCATTTCCCAAACTCAAAA TATGTTATAAGGGGTGYGAT  CTCTTTCTCCTTTTATATCC 321 
PTGS2 GAGGTGAGAGTGTTTTAGAT  CATAAACTTAATTTTCAATCTTAT GAGGTGAGAGTGTTTTAGAT  CATAAACTTAATTTTCAATCTTAT 476 
TBXA2R GTTGAGTAGGTAGATGTG ATAACCTAAAAATCCCAAAA TAGTTTGGTTGTGATTAGG CCAAAAAACTATAAAATATCC 325 
 
1 from reference [8]  (references are listed in page 4 
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Figure S1. PTGS pathway expression profiling in CRC cell lines. (A) Expression profile of a panel 
of 5 colorectal cancer cell lines shows the same trends observed in primary colorectal tumor 
tissues (see Figure 1), being most transcripts downregulated or fully silenced. The only 
transcripts that keep or increase their expression levels are the PGE2 synthases (PTGES, PTGES2 
and PTGES3). As a reference, we included the mean expression values for the tumor tissues 
analyzed by real time PCR (Figure 1A). (B) Gene expression was analyzed by qRT-PCR in HCT116 
and its DNMT double knockout cell line, HCT116-DKO (referred to as DKO). Expression levels in 
DKO cells were normalized to HCT116. Black bars correspond to genes that undergo 
hypermethylation a large proportion of colorectal tumors and all of the 5 cell lines analyzed (see 
Figure 2A-D). PTGIS was only detected in DKO cells, not in HCT116, being the log2(DKO/HCT116) 
value arbitrary in this case (marked with a white *). No detectable levels of AKR1B1 and PTGFR, 
























































































































































































































































































Figure S2. DNA methylation beta values quantified with InfiniumMethylation450K 
arrays for a cohort of 19 mucosae from healthy individuals (green), 22 adjacent 
normal tissues (blue), 42 adenomas (yellow) and 64 colorectal cancers. Normal 
mucosae from healthy and CRC patients display comparable profiles, while altered 
patterns affect in a similar way adenomas and carcinomas. Data were obtained from 
Luo et al. (supplementary reference 7). 
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Figure S3: Mutations in PTGS pathway genes in CRC. (A) Mutation al rates of PTGS 
pathway genes in CRC (data obtained from the TCGA database). Deleterious 
mutation definition based on TCGA criteria. (B) Survival plot for CRC patients with 
and without deleterious mutations in PTGFR. Survival is greatly affected by the 
presence of deleterious mutations in this gene, which is frequently 
hypermethylated in colorectal tumors. 






















































































13% 2% 2% 2% 1% <1% 2% <1% <1% 1% 2% 0% 0% <1% 1% 2%
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P value = 0.009493 
B 
A 
Figure S4: Principal component analysis of DNA methylation profiles in genes of 
the COX pathway in normal mucosa from healthy individuals, and the adjacent 
normal mucosa and tumor sample of patients with colorectal cancer. Samples from 
the left and right colon are depicted with distinct markers.  
Cebola et al 18 

























































cox p.value= 0.000316  
cox p.value= 0.021761  
PTGS2 
PTGDR 
cox p.value= 0.019265  
PTGES 
cox p.value= 0.029642  
cox p.value= 0.006201 
PTGIS 
cox p.value= 0.035736  
PTGER4 
Figure S5. Survival analysis of CRC patients according to gene expression levels. Data were 
obtained from four datasets (GEO: GSE14333, GSE12945, GSE17536, GSE17537) with 
follow-up information available to analyze the survival rate depending on gene 
expression. The PrognoScan algorithm (Mizuno et al, 2009, supplementary reference 10) 
was used to classify the patients into either the High or Low expression group (minimum 
p-value approach). Survival curves were constructed using the Kaplan-Meier method. 
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